Skip to main content
Sign In
Bookshare Bolivia: Home
-A +A
  • Language
    • English
    • Spanish
Help

Search Results

Search results: 5
  • Strengthening a Workforce for Innovative Regulatory Science in Therapeutics Development

    Strengthening a Workforce for Innovative Regulatory Science in Therapeutics Development

    by Institute of Medicine • Steve Olson • Forum on Drug Discovery, Development, and Translation • Anne B. Claiborne • Board on Health Sciences Policy

    The development and application of regulatory science - which FDA has defined as the science of developing new tools, standards, and approaches to assess the safety, efficacy, quality, and performance of FDA-regulated products - calls for a well-trained, scientifically engaged, and motivated workfor... More

    Language: ENG
    Copyright: 2011
  • Envisioning a Transformed Clinical Trials Enterprise in the United States

    Envisioning a Transformed Clinical Trials Enterprise in the United States

    by Development • Anne B. Claiborne • Board on Health Sciences Policy • Rebecca A. English • Neil Weisfeld • Rapporteurs • Forum on Drug Discovery • Translation

    There is growing recognition that the United States' clinical trials enterprise (CTE) faces great challenges. There is a gap between what is desired - where medical care is provided solely based on high quality evidence - and the reality - where there is limited capacity to generate timely and prac... More

    Language: ENG
    Copyright: 2012
  • Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis

    Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis

    by Institute of Medicine • Forum on Drug Discovery, Development, and Translation • Anne B. Claiborne • Board on Health Sciences Policy • Rebecca A. English • Rita S. Guenther • Anna Nicholson

    To effectively treat patients diagnosed with drug-resistant (DR) tuberculosis (TB) and protect the population from further transmission of this infectious disease, an uninterrupted supply of quality-assured (QA), second-line anti-TB drugs (SLDs) is necessary. Patients diagnosed with multidrug-resist... More

    Language: ENG
    Copyright: 2013
  • Public Engagement and Clinical Trials: New Models and Disruptive Technologies

    Public Engagement and Clinical Trials: New Models and Disruptive Technologies

    by Institute of Medicine • Forum on Drug Discovery, Development, and Translation • Victoria Weisfeld • Anne B. Claiborne • Board on Health Sciences Policy • Rebecca A. English

    Clinical trials provide essential information needed to turn basic medical research findings into patient treatments. New treatments must be studied in large numbers of humans to find out whether they are effective and to assess any harm that may arise from treatment. There is growing recognition am... More

    Language: ENG
    Copyright: 2012
  • Facing the Reality of Drug-Resistant Tuberculosis

    Facing the Reality of Drug-Resistant Tuberculosis

    by Institute of Medicine • Steve Olson • Forum on Drug Discovery, Development, and Translation • Anne B. Claiborne • Board on Health Sciences Policy • Rebecca A. English • Rita S. Guenther

    An estimated 8.8 million people fell ill with tuberculosis (TB) in 2010 and 1.4 million died from the disease. Although antibiotics to treat TB were developed in the 1950s and are effective against a majority of TB cases, resistance to these antibiotics has emerged over the years, resulting in the g... More

    Language: ENG
    Copyright: 2012
Refine Search
Show More Results

Refine Search

Enter a 10 or 13 digit numerical ISBN code
Categories
Clear

Footer

  • About
  • Partners
  • Legal
  • Accessibility
  • Privacy
  • Contact
  • Blog
Bookshare® and Benetech® are registered trademarks of Beneficent Technology, Inc. This website is © Copyright 2002-2023, Beneficent Technology, Inc.